Path Drug Solutions

SEE PART III, LINE 1.

IN NOVEMBER 2017, THE PDS BOARD DISCUSSED DISSOLUTION PDS. IN 2018, A NUMBER OF ACTIVITIES WERE CARRIED OUT TO COMPLETE THE DISSOLUTION PROCESS, INCLUDING PRODUCT PATENT TRANSFERS FROM PDS TO PATH, ENGAGEMENT OF LEGAL COUNSEL FOR DISSOLUTION PROCEDURES, AND OTHER ADMINISTRATIVE WORK. ON DECEMBER 31, 2018, THE DISSOLUTION OF PDS WAS FORMALLY RECOGNIZED BY THE CALIFORNIA SECRETARY OF STATE.IN JANUARY 2018, FOLLOWING THE CONCLUSION OF THE PHASE 2 CLINICAL STUDY OF RILPIVIRINE LA, A LONG-ACTING INJECTABLE DRUG TO PREVENT INFECTION WITH HIV WHEN USED BEFORE EXPOSURE, PDS COMPLETED ALL REMAINING STUDY CLOSE-OUT ACTIVITIES. THE INVESTIGATIONAL NEW DRUG APPLICATION FOR RILPIVIRINE LA HAS BEEN PLACED IN AN INACTIVE STATUS WITH THE US FOOD AND DRUG ADMINISTRATION, AND THE PROJECT IS NOW FINISHED.IN 2018, PDS CONTINUED WORK TO REDUCE THE BURDEN OF VISCERAL LEISHMANIASIS, ALSO KNOWN AS KALA-AZAR. KALA-AZAR IS A PARASITIC DISEASE COMMON IN AFRICA AND ASIA AND IS ALMOST ALWAYS FATAL IF LEFT UNTREATED. PDS SUPPORTED THE GOVERNMENT OF NEPAL IN ACTIVE CASE DETECTION USING BOTH A CAMP-BASED APPROACH AND AN INDEX CASE-BASED APPROACH IN KALA-AZAR ENDEMIC DISTRICTS. PDS ALSO HOSTED AN INTERNATIONAL POST-KALA-AZAR DERMAL LEISHMANIASIS (PKDL) CONSORTIUM MEETING TO PROVIDE GUIDANCE ON IMPROVING DIAGNOSIS, TREATMENT, AND FOLLOW-UP OF PKDL CASES.TO BUILD CLINICAL RESEARCH CAPACITY IN INDIA, PDS WORKED TO FURTHER DEVELOP AND IMPLEMENT A CLINICAL RESEARCH TRAINING AND MENTORSHIP PROGRAM. THIS WORK WAS DONE IN COLLABORATION WITH THREE NATIONAL CLINICAL RESEARCH RESOURCE CENTERS SPECIALIZING IN PHARMACOVIGILANCE, RESEARCH ETHICS, AND DATA MANAGEMENT.